EXEL Stock Analysis: Exelixis | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 13.563m USD | 12M Return: 21% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 133M
EPS Trend: 95.9%
Qual. Beats: 0
Rev. Trend: 96.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Exelixis, Inc. is a U.S.-based oncology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its marketed portfolio is anchored by cabozantinib, the active ingredient in both CABOMETYX (advanced renal cell carcinoma) and COMETRIQ (metastatic medullary thyroid cancer), and also includes COTELLIC, a MEK inhibitor used in combination therapy for advanced melanoma. Beyond oncology, the company markets MINNEBRO, an oral mineralocorticoid receptor blocker approved for hypertension in Japan through a regional partner.
The company is advancing a pipeline of experimental oncology candidates, including kinase inhibitors (zanzalintinib), a USP1 inhibitor for BRCA-mutated tumors (XL309), and several antibody-drug conjugates and bispecific antibodies (XB010, XB628, XB371). Exelixis supplements its internal R&D with an extensive network of research collaborations and license agreements with major pharmaceutical and biotechnology partners, including Ipsen, Takeda, Roche/Genentech, Bristol-Myers Squibb, and Daiichi Sankyo-a licensing-heavy model common among biotech firms seeking to extend geographic reach and share development risk. Incorporated in 1994 and headquartered in Alameda, California, Exelixis operates within the biotechnology sub-industry of the broader health care sector.
- CABOMETYX sales growth drives revenue and label expansions
- Zanzalintinib and ADC pipeline catalysts advance through clinical trials
- Ipsen Takeda partnerships deliver ex-US royalty revenue
| Net Income: 833.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.35 > 0.02 and ΔFCF/TA 8.12 > 1.0 |
| NWC/Revenue: 35.26% < 20% (prev 43.39%; Δ -8.12% < -1%) |
| CFO/TA 0.36 > 3% & CFO 924.7m > Net Income 833.4m |
| Net Debt (-607.7m) to EBITDA (1.02b): -0.60 < 3 |
| Current Ratio: 3.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (267.3m) vs 12m ago -7.24% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 87.48% > 50% (prev 81.03%; Δ 6.46% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.32 (Total Current Assets 1.21b - Total Current Liabilities 371.0m) / Total Assets 2.59b |
| B: -0.08 (Retained Earnings -215.8m / Total Assets 2.59b) |
| C: 0.36 (EBIT TTM 986.4m / Avg Total Assets 2.72b) |
| D: 2.94 (Book Value of Equity 1.94b / Total Liabilities 657.8m) |
| Altman-Z'' = 7.38 = AAA |
| DSRI: 1.13 (Receivables 328.9m/281.6m, Revenue 2.38b/2.30b) |
| GMI: 1.00 (GM 96.78% / 96.44%) |
| AQI: 1.00 (AQ_t 0.39 / AQ_t-1 0.39) |
| SGI: 1.03 (Revenue 2.38b / 2.30b) |
| TATA: -0.04 (NI 833.4m - CFO 924.7m) / TA 2.59b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of July 04, 2026, the stock is trading at USD 55.85 with a total of 2,364,000 shares traded. Over the past week, the price has changed by +4.92%, over one month by +8.24%, over three months by +26.99% and over the past year by +21.02%.
Current recommended Stop Loss: 54.00 (which is 3.3% or 1.2 ATR below the current price).
Exelixis has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy EXEL.
- StrongBuy: 9
- Buy: 1
- Hold: 9
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 49.5 | -11.4% |
P/E Trailing = 17.8676
P/E Forward = 17.2117
P/S = 5.7096
P/B = 7.0651
P/EG = 2.2685
Revenue TTM = 2.38b USD
EBIT TTM = 986.4m USD
EBITDA TTM = 1.02b USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 169.5m USD (from shortLongTermDebtTotal, last quarter) (leases 169.5m already included)
Net Debt = -607.7m USD (calculated: Debt 169.5m - CCE 777.2m)
Enterprise Value = 13.0b USD (13.6b + Debt 169.5m - CCE 777.2m)
Interest Coverage Ratio = unknown (Ebit TTM 986.4m / Interest Expense TTM 0.0)
EV/FCF = 14.14x (Enterprise Value 13.0b / FCF TTM 916.4m)
FCF Yield = 7.07% (FCF TTM 916.4m / Enterprise Value 13.0b)
FCF Margin = 38.58% (FCF TTM 916.4m / Revenue TTM 2.38b)
Net Margin = 35.08% (Net Income TTM 833.4m / Revenue TTM 2.38b)
Gross Margin = unknown ((Revenue TTM 2.38b - Cost of Revenue TTM 84.5m) / Revenue TTM)
Tobins Q-Ratio = 5.00 (Enterprise Value 13.0b / Total Assets 2.59b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 169.5m)
Taxrate = 16.92% (169.8m / 1.00b)
NOPAT = 819.5m (EBIT 986.4m * (1 - 16.92%))
Current Ratio = 3.26 (Total Current Assets 1.21b / Total Current Liabilities 371.0m)
Debt / Equity = 0.09 (Debt 169.5m / totalStockholderEquity, last quarter 1.94b)
Debt / EBITDA = -0.60 (Net Debt -607.7m / EBITDA 1.02b)
Debt / FCF = -0.66 (Net Debt -607.7m / FCF TTM 916.4m)
Total Stockholder Equity = 2.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.69% (Net Income 833.4m / Total Assets 2.59b)
RoE = 40.21% (Net Income TTM 833.4m / Total Stockholder Equity 2.07b)
RoCE = 44.38% (EBIT 986.4m / Capital Employed (Total Assets 2.59b - Current Liab 371.0m))
RoIC = 38.95% (NOPAT 819.5m / Invested Capital 2.10b)
WACC = 7.93% (E(13.6b)/V(13.7b) * Re(8.03%) + D(169.5m)/V(13.7b) * Rd(0.0%) * (1-Tc(0.17)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.22 | Cagr: -6.77%
[DCF] Terminal Value 77.97% ; FCFF base≈858.7m ; Y1≈984.4m ; Y5≈1.45b
[DCF] Fair Price = 89.15 (EV 21.8b - Net Debt -607.7m = Equity 22.4b / Shares 251.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.94 | EPS CAGR: 91.34% | SUE: 0.64 | # QB: 0
Revenue Correlation: 96.92 | Revenue CAGR: 13.33% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.89 | Chg30d=-1.26% | Revisions=+29% | Analysts=10
EPS current Year (2026-12-31): EPS=3.54 | Chg30d=-0.79% | Revisions=+47% | GrowthEPS=+15.0% | GrowthRev=+12.0%
EPS next Year (2027-12-31): EPS=4.00 | Chg30d=-1.21% | Revisions=+33% | GrowthEPS=+12.9% | GrowthRev=+12.4%
[Analyst] Revisions Ratio: +47%